The Male Hypogonadism drugs in development market research report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Male Hypogonadism. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued products.

GlobalData tracks 22 drugs in development for Male Hypogonadism by 20 companies/universities/institutes. The top development phase for Male Hypogonadism is phase ii with seven drugs in that stage. The Male Hypogonadism pipeline has 21 drugs in development by companies and one by universities/ institutes. Some of the companies in the Male Hypogonadism pipeline products market are: IASO BioMed, TesoRx Pharma and Viramal.

The key targets in the Male Hypogonadism pipeline products market include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR), Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR), and Voltage Dependent Anion Selective Channel Protein 1 (Outer Mitochondrial Membrane Protein Porin 1 or Plasmalemmal Porin or Porin 31HL or VDAC1).

The key mechanisms of action in the Male Hypogonadism pipeline product include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Agonist with 13 drugs in Filing rejected/Withdrawn. The Male Hypogonadism pipeline products include eight routes of administration with the top ROA being Oral and four key molecule types in the Male Hypogonadism pipeline products market including Small Molecule, and Peptide.

Male Hypogonadism overview

Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass, and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea. Treatment includes hormone replacement.

For a complete picture of Male Hypogonadism’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.